International Consortium Formed by Nozomi MedAlliance, TheraNova, and Global Expansion Solutions/Investable Solutions Selected for “TOKYO SUTEAM“.
The Tokyo Metropolitan Government’s “SUTEAM” (Startup Support Expansion Program with Diverse Stakeholders) is a leading initiative that connects organizations, universities, corporations, and venture capital firms to foster startup growth and innovation in Tokyo. This program focuses on deep tech startups, offering tailored support ranging from academia collaborations to commercialization and global expansion guidance.
The "Tokyo-Silicon Valley MedTech Launchpad"
An international consortium comprising Nozomi MedAlliance K.K. (Tokyo), TheraNova LLC (Silicon Valley), and Global Expansion Solutions / Investable Solutions (Silicon Valley, Seoul, Middle East) has been selected to participate in the Tokyo Metropolitan Government’s startup support initiative “TOKYO SUTEAM.” The consortium will launch the “Tokyo-Silicon Valley MedTech Launchpad,” connecting Japanese medical innovation with U.S. market opportunities.
The program addresses a critical gap: Japanese MedTech companies find it challenging to expand into the U.S. market, resulting in missed commercial opportunities, lower valuations and unattainable unicorn potential. The Tokyo-Silicon Valley MedTech Launchpad provides early-stage companies with structured support to validate technologies in U.S. markets during seed and Series A stages.
Running from November 2025 through April 2027, the program will support 20 medical device startups, including diagnostics, therapeutics, AI, and digital health across two cohorts of 10 companies each. The selected startups will participate in a two-stage acceleration process:
Stage 1 – expert mentoring on clinical data validation, product-market fit analysis, FDA regulatory pathways, intellectual property strategy, U.S. healthcare reimbursement, and venture capital preparation.
Stage 2 – top performers travel to California for hands-on business development: curated investor meetings with medical-focused VCs, partnership negotiations with hospital systems and medical device companies, FDA pre-submission processes, and pitch events before industry professionals.
The program delivers measurable outcomes through FDA pre-submissions, provisional patent filings, business partnerships, and acceptance into international acceleration programs.
More information will be found on the program’s website: www.tokyomedtech.com
About the consortium partners
Nozomi MedAlliance (Tokyo, Japan) (www.nozomimed.com )
A MedTech-specialized company supporting global expansion of Japan-origin medical devices and digital health technologies. Strategically partnered with the University of Tokyo and National Cancer Center Japan, the company promotes next-generation medical innovation.
Contact information: Jack Claar, Medical Director; email: info@nozomimed.com;
TheraNova (San Francisco, California) (www.theranova.com)
A medical device foundry based in San Francisco providing bespoke support helping international companies enter the US med-tech market. Over 20 medical device products built, obtaining 14 FDA authorizations, grants, and approvals.
Contact Information: Eran Steinberg, Chief Science Officer; email: esteinberg@theranova.com;
Investable Solutions (Silicon Valley, Seoul, Middle East) (https://globalexpansion.solutions)
A global accelerator with bases in Silicon Valley, Seoul, and the Middle East operating under the brand Global Expansion Solutions. Supported over 500 companies with over $1.4B in cumulative exits.
Contact information: Aaron Rothenberg, Founding Partner; email: aaron@investable.solutions;
